Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf210 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Simon E Koele und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology, and Toxicology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Neth…. Hauptthemen laut MEDLINE: Moxifloxacin, Antitubercular Agents, Diarylquinolines, Nitroimidazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EDCTP2 programme, German Ministry for Education and Research, German Center for Infection Research.
Abstract (Originalsprache)
Introduction
Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinones with demonstrated bactericidal activity. We aimed to assess the effects of sutezolid or delpazolid co-administered with bedaquiline, delamanid and moxifloxacin on the QTcF interval (Fridericia’s correction). Furthermore, we developed a population pharmacodynamic model to assess the effects of drug exposure on the QTcTBT interval (TB-specific correction).
Methods
Participants were randomized to receive standard-dose bedaquiline, delamanid and moxifloxacin with varying doses of either sutezolid (no sutezolid, 600 mg daily, 1200 mg daily, 600 mg twice daily, 800 mg twice daily) or delpazolid (no delpazolid, 400 mg daily, 800 mg daily, 1200 mg daily, 800 mg twice daily). The QTc interval was determined using weekly ECG assessments.
Results
Data from 149 participants, yielding 2373 ECG observations were available for analysis. Nine participants (6.0%) experienced a Grade 3 QTcF prolongation as defined by the Common Terminology Criteria for Adverse Events v5.0. The population pharmacodynamic model predicted a 13.2 ms (95% CI: 10.9–15.3) increase of the QTcTBT in the first week of treatment, but no further increase after that. The exposure of bedaquiline’s M2 metabolite was found to drive part of the QTcTBT. No exposure–response relationship was identified for the other drugs investigated.
Conclusions
The drug regimens containing standard doses of bedaquiline, delamanid and moxifloxacin, and varying doses of sutezolid or delpazolid were not found to pose a high cardiac risk in a population without further QTc-relevant risk factors. However, close monitoring of the QTc interval remains essential in patients with TB treated with combination drug therapy with known QTc-prolonging drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Pharmacology, and Toxicology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
- Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
- National Institute for Medical Research-Mbeya Medical Research Centre, Mbeya, Tanzania.
- Kibon'goto Infectious Disease Hospital, Moshi, Tanzania.
- Ifakara Health Institute, Bagamoyo Research and Training Unit, Dar es Salaam, Tanzania.
- The Aurum Institute, Johannesburg, South Africa.
ORCID-Profile: Simon E Koele, Jodie Schildkraut, Michael Hoelscher
Förderung
- EDCTP2 programme
- German Ministry for Education and Research
- German Center for Infection Research
- Swiss State Secretariat for Education, Research, and Innovation
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Koele, S. E., Stoycheva, K., Mtweve, C., Manyama, C., Mpagama, S., Mhimbira, F., Wallis, R., Ntinginya, N. E., Liyoyo, A., Huglin, B., Minja, L. T., Wagnerberger, L., Zumba, T., Noreña, I., Peter, D. D., Beattie, T., Makkan, H., Sloan, D. J., Te Brake, L., …, & PanACEA consortium (2025). Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf210
Vancouver
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, et al. Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf210
BibTeX
@article{Koele2025,
author = {Koele, Simon E and Stoycheva, Krista and Mtweve, Cyprian and Manyama, Christina and Mpagama, Stellah and Mhimbira, Francis and Wallis, Robert and Ntinginya, Nyanda Elias and Liyoyo, Alphonce and Huglin, Beno and Minja, Lilian Tina and Wagnerberger, Larissa and Zumba, Tresphory and Noreña, Ivan and Peter, Daud D and Beattie, Trevor and Makkan, Heeran and Sloan, Derek J and Te Brake, Lindsey and Aarnoutse, Rob E and McHugh, Timothy D and Wildner, Leticia and Schildkraut, Jodie and Aldana, Brian H and Phillips, Patrick P J and Hoelscher, Michael and Svensson, Elin M and Heinrich, Norbert and PanACEA consortium, PanACEA consortium},
title = {Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf210}
}
EUVIMED